AcuCort
AcuCort is a Swedish specialty pharmaceutical company that develops and commercializes cortisone-based oral dissolving films (Zeqmelit®) for severe allergic reactions, croup, nausea, and COVID-19 symptoms, distributing through partnerships across the Nordics and Europe.
- Company typePublic
- Founded2006
- HeadquartersHelsingborg, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What AcuCort does
AcuCort AB is a Swedish specialty pharmaceutical company that develops and commercializes user-friendly drug formulations based on existing, well-documented active substances. Its core product is Zeqmelit®, a cortisone-based oral dissolving film placed on the tongue for rapid administration in severe allergic reactions, croup, nausea, and COVID-19-related symptoms; the company also references ISICORT as an additional pipeline asset. The underlying technology is an oral-film drug delivery platform that addresses administration challenges in emergency situations where patients cannot swallow tablets, and Zeqmelit® holds regulatory approvals across Sweden, Denmark, Norway, and Finland.
AcuCort operates a capital-light, partnership-driven commercialization model rather than building a direct sales force. Distribution is executed through two strategic partners: Unimedic Pharma, which handles the Nordic region, and Glenmark Pharmaceuticals, which covers Germany, the Netherlands, the Czech Republic, Austria, Slovakia, and Ukraine under a January 2026 agreement. Revenue is recognized when these distribution partners purchase product, with a December 2025 order from Unimedic valued at EUR 112,000 representing the first quantified commercial transaction and supporting Q2 2026 financials. Pricing is managed through regulatory and reimbursement channels and is not publicly disclosed.
The company is publicly listed on the Spotlight Stock Market under ticker ACUC, is headquartered at Medicon Village in Lund, Sweden, and is led by CEO Jonas Jönmark with Business Development Director Anna Chérouvrier Hansson overseeing partnership expansion. AcuCort has funded operations through rights issues in 2023 and 2025 and continues to pursue geographic and indication expansion, including FDA approval in the United States and label extensions for Zeqmelit® beyond acute allergic reactions.
AcuCort firmographics
Firmographics- Name
- AcuCort
- Legal name
- AcuCort AB
- Website
- https://acucort.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- AcuCort is a Swedish specialty pharmaceutical company that develops and commercializes cortisone-based oral dissolving films (Zeqmelit®) for severe allergic reactions, croup, nausea, and COVID-19 symptoms, distributing through partnerships across the Nordics and Europe.
- Ownership category
- akta.pro rank
AcuCort industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC)
- akta.pro secondary industry
- Cold, Flu & Cough Remedies (HLAIADAB)
Keywords
Where AcuCort is headquartered
LocationHeadquarters
- HQ city
- Helsingborg
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
AcuCort business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales (Zeqmelit®): AcuCort generates revenue through the sale of its pharmaceutical product Zeqmelit®, distributed through partnership agreements. Revenue is realized when distribution partners purchase products, with the December 2025 order from Unimedic valued at EUR 112,000 for Nordic market coverage.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
AcuCort product offering
Product offeringCore offering
AcuCort develops and commercializes Zeqmelit®, a cortisone-based fast-dissolving oral film placed on the tongue for the treatment of severe acute allergic reactions, croup, nausea, and COVID-19-related symptoms. The company's focus is on reformulating existing, well-documented active substances into user-friendly dosage forms that address high unmet medical need and simplify administration in emergency situations where patients may struggle to swallow tablets.
Product overview
AcuCort develops and commercializes smart drugs based on existing and well-documented substances in treatment areas with high unmet medical need. The company's core product is Zeqmelit®, a cortisone-based oral film. The company also mentions ISICORT as another innovative treatment. The portfolio focuses on drugs that add benefits such as simplicity of administration, targeting conditions including severe allergic reactions, croup, nausea, and COVID-19-related symptoms.
Differentiator
Problem solved
Functional benefit
Brands
- Zeqmelit®: Cortisone-based oral film for treating severe allergic reactions, croup, nausea, and COVID-19-related symptoms. Approved in Sweden, Denmark, Norway, and Finland.
- ISICORT
Products and services
- Zeqmelit®
Quantifiable outcome
- Zeqmelit® approved in Sweden, Denmark, Norway, and Finland
Companies that use AcuCort
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
AcuCort technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
AcuCort partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Glenmark PharmaceuticalscoreGlenmark Pharmaceuticals partnership covers marketing and distribution of Zeqmelit® in Germany, Netherlands, Czech Republic, Austria, Slovakia, and Ukraine. This represents a significant expansion of AcuCort's European commercial footprint through an established pharmaceutical distribution partner. CEO Jonas Jönmark has emphasized the strategic value of this partnership for European market development.
- Unimedic PharmacoreUnimedic Pharma serves as AcuCort's Nordic distribution partner, handling sales and logistics of Zeqmelit® across Sweden, Denmark, Norway, and Finland. A recent order valued at EUR 112,000 was placed for Q2 2026 delivery, demonstrating ongoing commercial activity in the Nordic market where Zeqmelit® holds regulatory approvals.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
AcuCort competitors and assessment
Company assessmentBroad incumbents
- Mylan N.V. (Viatris): Large global generics company with significant cortisone and respiratory/allergy franchises, including EpiPen-adjacent emergency allergy products. Comparable by therapeutic category (corticosteroids, allergy) and by OTC/prescription pharmaceutical distribution.
- Teva Pharmaceutical Industries: Global generics leader with broad corticosteroid and respiratory product portfolios, including orally-administered steroid formulations. Comparable by therapeutic category and competing in similar indication spaces including croup and allergic conditions.
- Hikma Pharmaceuticals PLC: UK-listed specialty generics company with a strong corticosteroids portfolio and a similar partnership-based commercialization model across Europe and the Middle East. Comparable by therapeutic category and distribution-driven go-to-market.
- Camurus AB: Swedish specialty pharma using proprietary drug delivery technology (FluidCrystal) to develop improved formulations of existing substances, with global commercialization experience. Anna Chérouvrier Hansson (AcuCort's BD Director) previously worked at Camurus, evidencing comparable platform strategy.
Others
- Recipharm AB: Swedish pharmaceutical contract development and manufacturing organization (CDMO) with extensive ODF and oral solid dose capabilities. Comparable as a potential manufacturing partner and as a Swedish pharma ecosystem peer serving similar small-molecule, reformulation-oriented clients.
- Glenmark Pharmaceuticals Ltd. Indian-headquartered specialty pharma covering dermatology, respiratory, and allergy. Glenmark is AcuCort's actual distribution partner in Central and Eastern Europe but is also an adjacent peer given its parallel focus on respiratory and allergy therapeutics.
Direct peers
- ALK-Abelló A/S: Danish specialty pharma focused on allergy immunotherapy and emergency allergy treatment, overlapping with AcuCort's core acute allergic reaction indication. Comparable by indication focus and Nordic distribution reach.
- Orexo AB: Swedish specialty pharma developing drugs based on reformulation of established substances and a recognized leader in oral film (ODF/Zy Sal/Abstral) drug delivery technology. Closest comparable by geography, technology platform, and reformulation strategy, and also listed on a Swedish venue.
Regional players
- Calliditas Therapeutics AB: Swedish specialty pharma developing novel formulations of existing substances (budesonide) for inflammatory and orphan indications. Comparable as a small/mid-cap Swedish public company applying formulation technology to expand established APIs into new indications.
Emerging players
- Crossject SA: French specialty pharma developing needle-free, ready-to-use emergency drug delivery systems, including for severe allergic reactions. Comparable as a small-cap European company reinventing the delivery of established molecules in emergency settings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
AcuCort social profiles
Digital presenceAcuCort financial estimates
Financial estimateRevenue estimate
Valuation estimate
AcuCort leadership team
Management profileNumber of profiles
Profiles3 records
AcuCort funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AcuCort M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AcuCort
What does AcuCort do?
AcuCort develops and commercializes Zeqmelit®, a cortisone-based fast-dissolving oral film placed on the tongue for the treatment of severe acute allergic reactions, croup, nausea, and COVID-19-related symptoms. The company's focus is on reformulating existing, well-documented active substances into user-friendly dosage forms that address high unmet medical need and simplify administration in emergency situations where patients may struggle to swallow tablets.
Is AcuCort a public or private company?
AcuCort is a public company. It is classified as public and is currently operating.
When was AcuCort founded?
AcuCort was founded in 2006. It employs 1 to 10 people.
Where is AcuCort based?
AcuCort is headquartered in Helsingborg, Sweden, in the Europe region.
How does AcuCort make money?
One revenue line is on record: pharmaceutical Product Sales (Zeqmelit®).
Who are AcuCort's main competitors?
Broad incumbents on record are Mylan N.V. (Viatris), Teva Pharmaceutical Industries, Hikma Pharmaceuticals PLC and Camurus AB. Others are Recipharm AB and Glenmark Pharmaceuticals Ltd.. Direct peers are ALK-Abelló A/S and Orexo AB. Calliditas Therapeutics AB is listed as a regional player. Crossject SA is listed as an emerging player.
Does AcuCort have an API?
No public API is recorded for AcuCort.
What industry is AcuCort in?
AcuCort's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIADAC, Allergy, Sinus & Respiratory (Non-Asthma), with a secondary code of HLAIADAB, Cold, Flu & Cough Remedies. Its NAICS code is 32541 and its SIC code is 2833.